Amedisys Inc (NASDAQ:AMED) has been given an average rating of “Buy” by the seventeen research firms that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $191.53.
Several analysts recently commented on AMED shares. BidaskClub downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. SunTrust Banks upped their price target on shares of Amedisys from $225.00 to $240.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Oppenheimer reiterated a “buy” rating and issued a $215.00 price target on shares of Amedisys in a research report on Monday, April 27th. Royal Bank of Canada reiterated a “buy” rating and issued a $218.00 price target on shares of Amedisys in a research report on Sunday, May 10th. Finally, Zacks Investment Research upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $193.00 price target for the company in a research report on Friday, May 1st.
Shares of NASDAQ:AMED traded down $1.35 during trading on Friday, hitting $204.28. 12,286 shares of the company were exchanged, compared to its average volume of 632,773. The stock has a market capitalization of $6.66 billion, a P/E ratio of 53.16, a PEG ratio of 3.11 and a beta of 0.95. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.48 and a quick ratio of 1.48. Amedisys has a 12-month low of $115.41 and a 12-month high of $218.44. The firm’s 50 day moving average price is $186.62 and its 200-day moving average price is $180.52.
In related news, insider David L. Kemmerly sold 23,437 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $175.32, for a total value of $4,108,974.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Sharon Brunecz sold 2,185 shares of the stock in a transaction dated Friday, June 19th. The shares were sold at an average price of $196.00, for a total transaction of $428,260.00. Following the completion of the sale, the insider now directly owns 23,327 shares in the company, valued at $4,572,092. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,331 shares of company stock worth $6,786,676. Corporate insiders own 2.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of AMED. FMR LLC grew its stake in Amedisys by 13.4% in the 1st quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock valued at $45,703,000 after acquiring an additional 43,844 shares during the last quarter. Private Advisor Group LLC acquired a new stake in Amedisys in the 4th quarter valued at about $340,000. First Allied Advisory Services Inc. acquired a new stake in Amedisys in the 4th quarter valued at about $221,000. Aviva PLC acquired a new stake in Amedisys in the 4th quarter valued at about $2,040,000. Finally, Rafferty Asset Management LLC acquired a new stake in Amedisys in the 4th quarter valued at about $339,000. 88.21% of the stock is currently owned by hedge funds and other institutional investors.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.